Adverum Q2 net loss $49.2M, cash $44.4M; ARTEMIS Phase 3 enrollment ahead of schedule

Adverum Biotechnologies, Inc.

2025-Q2 EPS reported -$4.59

Net loss $49.2M ($2.34/sh) vs $30.5M ($1.46/sh) YoY; R&D spend up to $37.1M on ARTEMIS trial.
Cash $44.4M at June 30, 2025; expected to fund operations into Q4 2025.
ARTEMIS Phase 3 enrollment ahead of expectations; completion Q1 2026, topline data 1H 2027.
Announced $10M PIPE with Frazier Life Sciences at $2.24/share, closing Aug 12, 2025.
LUNA Phase 2 two-year data planned Q4 2025; AQUARIUS Phase 3 start pending funding in Q4 2025.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.